{"doi":"10.1016/j.bbcan.2017.03.008","title":"Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer","abstract":null,"journal":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","year":2017,"id":596212,"datarank":0.5050943744979712,"base_score":3.367295829986474,"endowment":3.367295829986474,"self_citation_contribution":0.5050943744979712,"citation_network_contribution":0.0,"self_endowment_contribution":0.5050943744979712,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":714203,"name":"Fang Yang","orcid":"0009-0008-5609-4196","position":1,"is_corresponding":false},{"id":1233888,"name":"Yucai Wang","orcid":"0000-0001-6046-2934","position":2,"is_corresponding":false},{"id":1526839,"name":"Xiaoxiang Guan","orcid":null,"position":3,"is_corresponding":false},{"id":861436,"name":"Doudou Huang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer","abstract":"Based on the prominent role estrogen receptor (ER) plays in breast cancer, endocrine therapy has been developed to block the ER pathway and has shown great effectiveness. Fulvestrant, the first selective ER down-regulator (SERD), was demonstrated to completely suppress ERα and notably efficient. However, resistance to fulvestrant occurs, either intrinsic or acquired during the treatment. Several potential mechanisms inducing fulvestrant resistance have been proposed, composed of activated ERα-independent compensatory growth factor signaling, stimulated downstream kinases, altered cell cycle mediators, etcetera. Experimentally, combinations of fulvestrant with targeted treatments were reported to eliminate the resistance and improve the effect of fulvestrant. Meanwhile, some clinical trials associated with the targeted combination therapies are in progress. This review focuses on the underlying mechanisms that contribute to fulvestrant resistance in ER-positive breast cancer and provides an overview of combined fulvestrant with targeted agents to shed light on optimal therapies for patients with ER-positive breast cancer.","is_dataset_classified":null,"base_score":3.367295829986474,"endowment":3.367295829986474,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28344099","pmcid":null,"openalex_id":"https://openalex.org/W2598503582","authors":[],"funders":[{"funder_name":"National Natural Science Foundation of China","grant_id":"81470357","title":null},{"funder_name":"Foundation for Clinical Medicine Science and Technology Special Project of the Jiangsu Province, China","grant_id":"BL2014071","title":null}],"total_grants":2,"fwci":3.4041,"citation_percentile":0.92204678,"influential_citations":0,"citation_trend":[{"year":2017,"count":2},{"year":2018,"count":3},{"year":2019,"count":6},{"year":2020,"count":6},{"year":2021,"count":1},{"year":2022,"count":3},{"year":2023,"count":1},{"year":2024,"count":3},{"year":2025,"count":3}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0304419X17300033?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0304419X17300033?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.bbcan.2017.03.008","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28344099","host_type":"repository"}],"fields_of_study":["Estrogen and related hormone effects","HER2/EGFR in Cancer Research","Advanced Breast Cancer Therapies"],"mesh_terms":["Animals","Breast Neoplasms","Female","Humans","Receptors, Estrogen","Signal Transduction","Down-Regulation","Drug Resistance, Neoplasm","Estrogen Receptor Modulators"],"keywords":["Fulvestrant","Metastatic breast cancer","Estrogen receptor","Breast cancer","Medicine","Cancer","Cancer research","Oncology","Internal medicine","Mechanism","Estrogen Receptor-positive Metastatic Breast Cancer","Fulvestrant Resistance","Targeted Combination Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T06:27:32.622309Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}